Personalizing therapy in type 2 diabetes

New study suggests renoprotective effect of SGLT2 inhibitor

In a clinical trial of patients with type 2 diabetes, Hiddo Heerspink and others showed that canagliflozin (a sodium-glucose cotransporter 2 inhibitor) slowed kidney function decline to a greater extent than glimepiride (a sulfonylurea). Investigators analyzed data on... Lees meer

Prof. Hiddo L. Heerspink wins the Galenus Award

Prof. Hiddo L. Heerspink is the winner of this year’s Galenus Award. This research price is rewarded to a scientist (or research team) who has had a significant impact on fundamental or clinical pharmacotherapeutic research. The award ceremony takes place on... Lees meer

Thesis defence

Bauke Schievink successfully defended his thesis entitled ” Integrating biomarkers to predict renal and cardiovascular drug efficacy: PRE score applications from drug registration to personalized medicine”. In his thesis, Bauke describes the clinical... Lees meer